Table of Contents
ISRN Immunology
Volume 2013, Article ID 548312, 8 pages
Clinical Study

Retrospective Analysis of Efficacy and Safety of Tocilizumab Treatment in Patients with Severe Systemic-Onset Juvenile Idiopathic Arthritis Followed for 12 Months

1Federal State Budgetary Institution “Scientific Center of Children’s Health,” Russian Academy of Medical Sciences, Moscow 119991, Russia
2I. M. Sechenov First Moscow State Medical University, Moscow 119991, Russia

Received 17 June 2013; Accepted 11 July 2013

Academic Editors: A. Boon, I. Hellstrom, and E. K. Kapsogeorgou

Copyright © 2013 E. I. Alexeeva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The results of the retrospective study evaluating efficacy and safety of tocilizumab treatment in 75 patients with severe systemic-onset juvenile idiopathic arthritis refractory to standard immunosuppressive therapy are presented in the paper. Inactive disease was documented in 64% of patients after 6 months of treatment and in 73% of patients after 12 months. Adverse events manifested as mild and moderate infections as well as laboratory abnormalities: leukopenia, neutropenia, and elevated aminotransferase levels.